Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Total Non-Current Liabilities (2016 - 2022)

Historic Total Non-Current Liabilities for Spero Therapeutics (SPRO) over the last 7 years, with Q4 2022 value amounting to $48.9 million.

  • Spero Therapeutics' Total Non-Current Liabilities fell 4039.11% to $48.9 million in Q4 2022 from the same period last year, while for Dec 2022 it was $48.9 million, marking a year-over-year decrease of 4039.11%. This contributed to the annual value of $48.9 million for FY2022, which is 4039.11% down from last year.
  • According to the latest figures from Q4 2022, Spero Therapeutics' Total Non-Current Liabilities is $48.9 million, which was down 4039.11% from $31.9 million recorded in Q3 2022.
  • Spero Therapeutics' Total Non-Current Liabilities' 5-year high stood at $82.4 million during Q1 2022, with a 5-year trough of $5.9 million in Q1 2018.
  • Its 5-year average for Total Non-Current Liabilities is $29.1 million, with a median of $19.3 million in 2019.
  • In the last 5 years, Spero Therapeutics' Total Non-Current Liabilities skyrocketed by 14569.29% in 2020 and then crashed by 4039.11% in 2022.
  • Spero Therapeutics' Total Non-Current Liabilities (Quarter) stood at $12.9 million in 2018, then skyrocketed by 48.92% to $19.3 million in 2019, then surged by 41.62% to $27.3 million in 2020, then soared by 200.66% to $82.0 million in 2021, then crashed by 40.39% to $48.9 million in 2022.
  • Its Total Non-Current Liabilities was $48.9 million in Q4 2022, compared to $31.9 million in Q3 2022 and $27.6 million in Q2 2022.